Management of Severe Hypoglycemia in Patients Treated with Basal Insulin

Immediate Insulin Dose Adjustment

Reduce the basal insulin dose by 10–20% (e.g., from 19 U to approximately 15–17 U) when a life‑threatening hypoglycemic episode occurs, even if the cause is not yet identified. 1

If the patient is conscious and can swallow, administer 15–20 g of fast‑acting carbohydrate immediately. 1
If the patient is unconscious or unable to take oral carbohydrates, give glucagon (injectable or nasal) promptly. 3
Re‑measure capillary glucose 15 minutes after treatment and repeat carbohydrate or glucagon administration if glucose remains <70 mg/dL. 1

Review all glucose‑lowering medications (e.g., sulfonylureas, meglitinides) that could contribute to hypoglycemia. 6
Verify injection timing to rule out incorrect timing or double‑dosing of basal insulin. 2
Consider residual insulin activity from a prior day’s dose as a possible cause. 3
Assess for inadequate food intake or increased physical activity that may lower glucose. 6
In patients with estimated GFR < 60 mL/min, adjust basal insulin to 0.1–0.2 U/kg/day to account for reduced renal clearance. 8

Check fasting blood glucose daily to evaluate basal insulin adequacy. 1
Specifically monitor glucose at the previous time of hypoglycemia (e.g., late morning) for recurrence. 1
Aim for a fasting plasma glucose target of 80–130 mg/dL (4.4–7.2 mmol/L). 1
If fasting glucose remains above target and no hypoglycemia occurs, increase the basal dose by 1–2 U every 3 days (cautious titration). 1

Patients with a recent severe hypoglycemic event have a high risk of recurrent episodes and may develop hypoglycemia unawareness. 9
A 2–3‑week period of strict hypoglycemia avoidance can help restore symptom awareness. 9
Ensure the patient has prescribed glucagon readily available for emergencies. 3
Provide comprehensive education on hypoglycemia recognition, self‑treatment, and when to seek emergency care. 6

Consider switching to a longer‑acting basal analog (e.g., U‑300 glargine or insulin degludec), which are associated with lower nocturnal hypoglycemia risk compared with U‑100 glargine. 5
Conversion is generally unit‑for‑unit, but for patients at high hypoglycemia risk a 10–20% dose reduction at the time of switch is advisable. 5